 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for GERN
 DateFirmActionFromTo Nov 2021BairdInitiates Coverage OnOutperform Aug 2020HC Wainwright & Co.MaintainsBuy Aug 2020StifelInitiates Coverage OnBuy
 View More Analyst...

The Latest Analyst Ratings For Geron

China Universal Asset Management Co. Ltd. lifted its position in shares of Geron Co. (NASDAQ:GERN - Free Report) by 367.9% in the 4th quarter, according to the company in its most recent Form 13F...

China Universal Asset Management Co. Ltd. Acquires 49,394 Shares of Geron Co. (NASDAQ:GERN)

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Gerons Chairman and Chief Executive Officer, is scheduled to present at...

Geron to Participate at Upcoming Investor Conferences in April

Geron Co. (NASDAQ:GERN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 50,950,000 shares, a...

Geron Co. (NASDAQ:GERN) Sees Large Growth in Short Interest

Investors in Geron Corp. (GERN) saw new options become available today, for the August 16th expiration...

Interesting GERN Put And Call Options For August 16th

Investors in Geron Corp. (GERN) saw new options become available today, for the May 3rd expiration...

GERN May 3rd Options Begin Trading

Geron Co. (NASDAQ:GERN  Get Free Report) shares saw unusually-strong trading volume on Monday after The Goldman Sachs Group raised their price target on the stock from $4.00 to $5.00. The...

Geron (NASDAQ:GERN) Sees Unusually-High Trading Volume Following Analyst Upgrade

Geron (NASDAQ:GERN  Free Report) had its price objective raised by The Goldman Sachs Group from $4.00 to $5.00 in a research report released on Friday, Benzinga reports. The brokerage...

The Goldman Sachs Group Boosts Geron (NASDAQ:GERN) Price Target to $5.00

Wedbush reiterated their outperform rating on shares of Geron (NASDAQ:GERN  Free Report) in a research report released on Friday morning, Benzinga reports. They currently have a $6.00 target...

Geron (NASDAQ:GERN) Earns Outperform Rating from Wedbush

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Geron prices $150M offering of common stock and warrants at $3.00 per share

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Volume (M)	9.74M
52-Wk High	$4.05
52-Wk Low	$1.64

GERN Geron Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals